Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDG-16177 Phase 1 Study in Healthy Subjects and Patients with Type 2 Diabetes
NCT04982705Phase 1Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IDG-16177 in type 2 diabetes mellitus (T2DM), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Adverse Events/Serious Adverse Events up to 9 weeks, Clinically Significant Change in Vital Signs up to 9 weeks and 2 more. Status: unknown.
02
Drugs
IDG-16177
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04982705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982705.